Market Place
Sourcing Support
Bristol Myers Squibb Presents New Data On Sotyktu Efficacy
27 Sep 2024 //
BUSINESSWIRE
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
10 Jun 2024 //
BIOPHARMADIVE
Sotyktu 4-Year Data Shows Durable Safety, Response In Psoriasis
16 May 2024 //
BUSINESSWIRE
BMS taps Mindy Kaling to join Ted Danson in Sotyktu promos
15 May 2024 //
FIERCE PHARMA
Kymera doubles down on protein degraders for immunology
04 Jan 2024 //
ENDPTS
Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113
27 Nov 2023 //
ACCESSWIRE
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy
11 Oct 2023 //
BUSINESSWIRE
BMS’s Sotyktu recommended for NHS use for adult patients with psoriasis
28 Jun 2023 //
PHARMAFILE
BMS says TYK2 inhibitor Sotyktu gains EU approval in psoriasis
29 Mar 2023 //
PRESS RELEASE
BMS debuts first psoriasis drug ad on Grammys, leading chorus of pharma brands
06 Feb 2023 //
ENDPTS
BMS holds on to high Sotyktu hopes, plays down Otelza threat
02 Feb 2023 //
FIERCE PHARMA
BMS Announces Positive CHMP Opinion for Once-Daily Sotyktu for Plaque Psoriasis
27 Jan 2023 //
BUSINESSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Nimbus posts psoriasis data on rival to Bristol Myers` Sotyktu
30 Nov 2022 //
FIERCEBIOTECH
Health Canada Has Approved (Pr)SOTYKTU (deucravacitinib tablets)
28 Nov 2022 //
BIOSPACE
Why Bristol Myers Squibb Stock Bounced Higher Today
22 Sep 2022 //
MOTLEY FOOL
Bristol Myers gets FDA approval for new type of psoriasis drug
11 Sep 2022 //
BIOPHARMADIVE
Bristol Myers Squibb Announces New Sotyktu Long-Term Data
10 Sep 2022 //
BUSINESSWIRE
U.S. Food and Drug Administration Approves Sotyktu
09 Sep 2022 //
BUSINESSWIRE
BMS heads for phase 3 lupus trial for TYK2 inhibitor this year
02 Jun 2022 //
FIERCEBIOTECH
BMS builds the case for psoriasis hopeful as it waits in regulatory limbo
13 May 2022 //
ENDPTS
BMS hints its TYK2 inhibitor could take on a form of lupus
29 Apr 2022 //
FIERCEBIOTECH
Bristol`s deucravacitinib not just another JAK drug, exec says
21 Jan 2022 //
FIERCEPHARMA
Amgen`s Otezla Shines Again in Psoriasis
03 Dec 2021 //
BIOSPACE
Bristol Myers up for high-stakes FDA autoimmune drug decision
01 Dec 2021 //
FIERCEPHARMA
BMS’ new JAK inhibitor enters regulatory pathways
01 Dec 2021 //
PMLIVE
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment
29 Nov 2021 //
BUSINESSWIRE
Amid JAK debacle, Bristol Myers settles in for FDA`s long review of potential
29 Nov 2021 //
ENDPTS
Analyst puts Amgen`s Otezla, Repatha, biosimilars on notice
23 Nov 2021 //
FIERCEPHARMA
BMS` deucravacitinib flunks midphase IBD trial
08 Oct 2021 //
FIERCEBIOTECH
BMS says deucravacitinib flops mid-stage ulcerative colitis study
07 Oct 2021 //
PRESS RELEASE
